Mars, Nina http://orcid.org/0000-0002-7259-5993
,
Koskela, Jukka T. http://orcid.org/0000-0002-0154-7222
Ripatti, Pietari http://orcid.org/0000-0002-6530-3243
Kiiskinen, Tuomo T. J. http://orcid.org/0000-0002-6306-8227
Havulinna, Aki S. http://orcid.org/0000-0002-4787-8959
Lindbohm, Joni V.
Ahola-Olli, Ari
Kurki, Mitja
Karjalainen, Juha
Palta, Priit
Neale, Benjamin M. http://orcid.org/0000-0003-1513-6077
Daly, Mark
Salomaa, Veikko http://orcid.org/0000-0001-7563-5324
Palotie, Aarno
Widén, Elisabeth
Ripatti, Samuli http://orcid.org/0000-0002-0504-1202
Article History
Received: 14 August 2019
Accepted: 13 February 2020
First Online: 7 April 2020
Competing interests
: A.P. is a member of the Pfizer Genetics Scientific Advisory Panel. V.S. has participated in a conference trip sponsored by Novo Nordisk and received an honorarium for participating in an advisory board meeting (unrelated to the present study). V.S. also has research collaboration with Bayer Ltd (unrelated to the present study). B.M.N. is a member of the scientific advisory board at Deep Genomics and a consultant for Camp4 Therapeutics, Takeda Pharmaceutical and Biogen.